{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T14:39:20Z","timestamp":1792852760821,"version":"4.5.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-cardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jjcc.2025.02.013","type":"journal-article","created":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T03:06:56Z","timestamp":1739502416000},"page":"473-479","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Development of new anticoagulants targeting coagulation factor XI and prospects for clinical use"],"prefix":"10.1016","volume":"85","author":[{"given":"Masahiro","family":"Ieko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumasa","family":"Ohmura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumiyoshi","family":"Naito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Kumano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jjcc.2025.02.013_bb0005","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jjcc.2025.02.013_bb0010","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1182\/blood-2014-04-571232","article-title":"Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials","volume":"124","author":"Van Es","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jjcc.2025.02.013_bb0015","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.017559","article-title":"Direct oral anticoagulant use: a practical guide to common clinical challenges","volume":"9","author":"Chen","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jjcc.2025.02.013_bb0020","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.ejvs.2014.05.001","article-title":"Editor\u2019s Choice - efficacy and safety of the new oral anticoagulants, dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials","volume":"48","author":"Kakkos","year":"2014","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.jjcc.2025.02.013_bb0025","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.7326\/M22-0511","article-title":"Comparative effectiveness and safety between apixaban, dabigatran, edoxaban, and rivaroxaban among patients with atrial fibrillation: a multinational population-based cohort study","volume":"175","author":"Lau","year":"2022","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jjcc.2025.02.013_bb0030","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.3390\/jcm13082277","article-title":"Comparing the real-world and clinical trial bleeding rates associated with oral anticoagulation treatment for atrial fibrillation","volume":"13","author":"Gue","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.jjcc.2025.02.013_bb0035","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1016\/j.jacc.2021.04.061","article-title":"Meta-analysis of reversal agents for severe bleeding associated with direct oral anticoagulants","volume":"77","author":"G\u00f3mez-Outes","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2025.02.013_bb0040","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1161\/ATVBAHA.109.197178","article-title":"Inhibition of factor XIa as a new approach to anticoagulation","volume":"30","author":"Schumacher","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jjcc.2025.02.013_bb0045","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1055\/s-0040-1710013","article-title":"Role of factor XIa and plasma kallikrein in arterial and venous thrombosis","volume":"120","author":"Visser","year":"2020","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jjcc.2025.02.013_bb0050","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.jacc.2021.06.010","article-title":"Factor XI inhibition to uncouple thrombosis from hemostasis: JACC review topic of the week","volume":"78","author":"Hsu","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2025.02.013_bb0055","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.thromres.2011.11.051","article-title":"Factor XI: hemostasis, thrombosis, and antithrombosis","volume":"129","author":"He","year":"2012","journal-title":"Thromb Res"},{"key":"10.1016\/j.jjcc.2025.02.013_bb0060","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1111\/jth.12435","article-title":"Evidence for factor IX-independent roles for factor XIa in blood coagulation","volume":"11","author":"Matafonov","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jjcc.2025.02.013_bb0065","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1182\/blood-2014-10-604587","article-title":"Activated factor XI increases the procoagulant activity of the extrinsic pathway by inactivating tissue factor pathway inhibitor","volume":"125","author":"Puy","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jjcc.2025.02.013_bb0070","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1161\/ATVBAHA.116.306925","article-title":"Factor XI as a therapeutic target","volume":"36","author":"Gailani","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jjcc.2025.02.013_bb0075","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1055\/s-0037-1603937","article-title":"Inhibition of factors XI and XII for prevention of thrombosis induced by artificial surfaces","volume":"44","author":"Tillman","year":"2018","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.jjcc.2025.02.013_bb0080","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1161\/CIRCULATIONAHA.122.062353","article-title":"Pharmacology and clinical development of factor XI inhibitors","volume":"147","author":"Greco","year":"2023","journal-title":"Circulation"},{"issue":"Suppl. 1","key":"10.1016\/j.jjcc.2025.02.013_bb0085","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/j.1538-7836.2009.03395.x","article-title":"Factor XI deficiency in humans","volume":"7","author":"Seligsohn","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jjcc.2025.02.013_bb0090","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1160\/TH10-05-0307","article-title":"Patients with severe factor XI deficiency have a reduced incidence of deep-vein thrombosis","volume":"105","author":"Salomon","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jjcc.2025.02.013_bb0095","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1161\/ATVBAHA.113.301598","article-title":"Targeting factor XI to prevent thrombosis","volume":"33","author":"Morrissey","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jjcc.2025.02.013_bb0100","doi-asserted-by":"crossref","first-page":"4113","DOI":"10.1182\/blood-2007-10-120139","article-title":"Reduced incidence of ischemic stroke in patients with severe factor XI deficiency","volume":"111","author":"Salomon","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jjcc.2025.02.013_bb0105","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1046\/j.1538-7836.2003.00195.x","article-title":"Inherited factor XI deficiency confers no protection against acute myocardial infarction","volume":"1","author":"Salomon","year":"2003","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jjcc.2025.02.013_bb0110","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1182\/blood-2016-09-742262","article-title":"Factor XI deficiency is associated with lower risk for cardiovascular and venous thromboembolism events","volume":"129","author":"Preis","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jjcc.2025.02.013_bb0115","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1056\/NEJM200003093421004","article-title":"High levels of coagulation factor XI as a risk factor for venous thrombosis","volume":"342","author":"Meijers","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2025.02.013_bb0120","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1161\/ATVBAHA.115.306954","article-title":"Factor XI deficiency protects against atherogenesis in apolipoprotein E\/factor XI double knockout mice","volume":"36","author":"Shnerb Ganor","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"Suppl. 1","key":"10.1016\/j.jjcc.2025.02.013_bb0125","first-page":"12","article-title":"Cellular interactions in hemostasis","volume":"26","author":"Hoffman","year":"1996","journal-title":"Haemostasis"},{"key":"10.1016\/j.jjcc.2025.02.013_bb0130","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s40560-016-0144-5","article-title":"Profiles of direct oral anticoagulants and clinical usage-dosage and dose regimen differences","volume":"4","author":"Ieko","year":"2016","journal-title":"J Intensive Care"},{"issue":"Suppl. 1","key":"10.1016\/j.jjcc.2025.02.013_bb0135","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1046\/j.1365-2516.2000.00053.x","article-title":"Factor XI deficiency and its management","volume":"6","author":"Bolton-Maggs","year":"2000","journal-title":"Haemophilia"},{"key":"10.1016\/j.jjcc.2025.02.013_bb0140","doi-asserted-by":"crossref","first-page":"3942","DOI":"10.1182\/blood-2011-03-339572","article-title":"Factor XIIa regulates the structure of the fibrin clot independently of thrombin generation through direct interaction with fibrin","volume":"118","author":"Konings","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jjcc.2025.02.013_bb0145","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1016\/j.jmb.2019.09.008","article-title":"Allosteric inhibition as a new mode of action for BAY 1213790, a neutralizing antibody targeting the activated form of coagulation factor XI","volume":"431","author":"Schaefer","year":"2019","journal-title":"J Mol Biol"},{"key":"10.1016\/j.jjcc.2025.02.013_bb0150","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/rth2.12186","article-title":"BAY 1213790, a fully human IgG1 antibody targeting coagulation factor XIa: first evaluation of safety, pharmacodynamics, and pharmacokinetics","volume":"3","author":"Thomas","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jjcc.2025.02.013_bb0155","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1182\/blood-2018-10-880849","article-title":"MAA868, a novel FXI antibody with a unique binding mode, shows durable effects on markers of anticoagulation in humans","volume":"133","author":"Koch","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jjcc.2025.02.013_bb0160","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1056\/NEJMoa2105872","article-title":"Abelacimab for prevention of venous thromboembolism","volume":"385","author":"Verhamme","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2025.02.013_bb0165","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/jth.15577","article-title":"Pharmacokinetics and pharmacodynamics of abelacimab (MAA868), a novel dual inhibitor of factor XI and factor XIa","volume":"20","author":"Yi","year":"2022","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jjcc.2025.02.013_bb0170","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1182\/blood.2021011725","article-title":"The contact activation inhibitor AB023 in heparin-free hemodialysis: results of a randomized phase 2 clinical trial","volume":"138","author":"Lorentz","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jjcc.2025.02.013_bb0175","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1161\/ATVBAHA.118.312328","article-title":"Contact activation inhibitor and factor XI antibody, AB023, produces safe, dose-dependent anticoagulation in a phase 1 first-in-human trial","volume":"39","author":"Lorentz","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jjcc.2025.02.013_bb0180","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1111\/jth.15744","article-title":"First randomized evaluation of safety, pharmacodynamics, and pharmacokinetics of BAY 1831865, an antibody targeting coagulation fac- tor XI and factor XIa, in healthy men","volume":"20","author":"Nowotny","year":"2022","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jjcc.2025.02.013_bb0185","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1161\/CIRCULATIONAHA.113.002033","article-title":"Evolution and emergence of therapeutic monoclonal antibodies: what cardiologists need to know","volume":"127","author":"Foltz","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2025.02.013_bb0190","article-title":"A rare cause of isolated prolonged activated partial thromboplastin time: an overview of prekallikrein deficiency and the contact system","volume":"9","author":"Riano","year":"2021","journal-title":"J Investig Med High Impact Case Rep"},{"key":"10.1016\/j.jjcc.2025.02.013_bb0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40119-024-00352-x","article-title":"Factor XI inhibitors: a new horizon in anticoagulation therapy","volume":"13","author":"Presume","year":"2024","journal-title":"Cardiol Ther"},{"issue":"23","key":"10.1016\/j.jjcc.2025.02.013_bb0200","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1001\/jama.2019.20687","article-title":"Effect of osocimab in preventing venous thromboembolism among patients undergoing knee arthroplasty: the FOXTROT randomized clinical trial","volume":"3","author":"Weitz","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.jjcc.2025.02.013_bb0205","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1055\/a-1384-3715","article-title":"Factor XI as a target for new anticoagulants","volume":"41","author":"Fredenburgh","year":"2021","journal-title":"Hamostaseologie"},{"key":"10.1016\/j.jjcc.2025.02.013_bb0210","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1111\/bcp.14732","article-title":"ONO-7684 a novel oral FXIa inhibitor: safety, tolerability, pharmacokinetics and pharmacodynamics in a first-in-human study","volume":"87","author":"Beale","year":"2021","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.jjcc.2025.02.013_bb0215","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13787","article-title":"Pharmacokinetics, pharmacodynamics, and safety of frunexian in healthy Chinese volunteer adults: a randomized dose-escalation phase I study","volume":"17","author":"Zhang","year":"2024","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.jjcc.2025.02.013_bb0220","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/S0140-6736(22)00456-1","article-title":"Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study","volume":"399","author":"Piccini","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jjcc.2025.02.013_bb0225","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S0140-6736(22)01588-4","article-title":"Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial","volume":"400","author":"Shoamanesh","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jjcc.2025.02.013_bb0230","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1161\/CIRCULATIONAHA.122.061612","article-title":"A multicenter, phase 2, randomized, placebo-controlled, double-blind, parallel-group, dose-finding trial of the oral factor XIa inhibitor asundexian to prevent adverse cardiovascular outcomes following acute myocardial infarction","volume":"146","author":"Rao","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2025.02.013_bb0235","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa2407105","article-title":"Asundexian versus apixaban in patients with atrial fibrillation","volume":"392","author":"Piccini","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2025.02.013_bb0240","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1056\/NEJMoa2113194","article-title":"Milvexian for the prevention of venous thromboembolism","volume":"385","author":"Weitz","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2025.02.013_bb0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.jstrokecerebrovasdis.2022.106742","article-title":"Rationale and design of the AXIOMATIC-SSP phase II trial: antithrombotic treatment with factor XIa inhibition to optimize management of acute thromboembolic events for secondary stroke prevention","volume":"31","author":"Sharma","year":"2022","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"10.1016\/j.jjcc.2025.02.013_bb0250","series-title":"Paper presented at: European Society of Cardiology 2022 conference, part 4, session 6 of 17","article-title":"AXIOMATIC-SSP: antithrombotic treatment with factor XIa inhibition to optimize management of acute thromboembolic events for secondary stroke prevention","author":"Sharma","year":"2022"},{"issue":"Suppl. 1","key":"10.1016\/j.jjcc.2025.02.013_bb0255","doi-asserted-by":"crossref","first-page":"i29","DOI":"10.1093\/eurheartjsupp\/suae013","article-title":"Factor XI inhibition in patients with acute coronary syndrome","volume":"26","author":"Raffo","year":"2024","journal-title":"Eur Heart J Suppl"},{"key":"10.1016\/j.jjcc.2025.02.013_bb0260","doi-asserted-by":"crossref","first-page":"4684","DOI":"10.1182\/blood-2010-04-277798","article-title":"Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk","volume":"116","author":"Zhang","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jjcc.2025.02.013_bb0265","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1146\/annurev-med-041217-010829","article-title":"Therapeutic antisense oligonucleotides are coming of age","volume":"70","author":"Bennett","year":"2019","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.jjcc.2025.02.013_bb0270","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1089\/nat.2016.0650","article-title":"The effects of 2\u2032-O-methoxyethyl containing antisense oligonucleotides on platelets in human clinical trials","volume":"27","author":"Crooke","year":"2017","journal-title":"Nucleic Acid Ther"},{"key":"10.1016\/j.jjcc.2025.02.013_bb0275","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1405760","article-title":"Factor XI antisense oligonucleotide for prevention of venous thrombosis","volume":"372","author":"B\u00fcller","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2025.02.013_bb0280","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13784","article-title":"Pharmacokinetics, pharmacodynamics, and safety of fesomersen, a novel antisense inhibitor of factor XI, in healthy Chinese, Japanese, and Caucasian volunteers","volume":"17","author":"Liu","year":"2024","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.jjcc.2025.02.013_bb0285","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1038\/s41598-017-02055-x","article-title":"Selection and characterization of a DNA aptamer inhibiting coagulation factor XIa","volume":"7","author":"Donkor","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jjcc.2025.02.013_bb0290","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.thromres.2017.06.015","article-title":"Generation and characterization of aptamers targeting factor XIa","volume":"156","author":"Woodruff","year":"2017","journal-title":"Thromb Res"},{"key":"10.1016\/j.jjcc.2025.02.013_bb0295","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1055\/a-2043-0346","article-title":"Factor XI inhibitors in early clinical trials: a meta-analysis","volume":"123","author":"Galli","year":"2023","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jjcc.2025.02.013_bb0300","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1007\/s40265-024-02049-w","article-title":"Therapeutic potential of FXI inhibitors: hype or hope?","volume":"84","author":"Galli","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.jjcc.2025.02.013_bb0305","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1111\/jth.12295","article-title":"Factor XII promotes blood coagulation independent of factor XI in the presence of long-chain polyphosphates","volume":"11","author":"Puy","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jjcc.2025.02.013_bb0310","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.5858\/2002-126-1382-TCS","article-title":"The contact system","volume":"126","author":"Kitchens","year":"2002","journal-title":"Arch Pathol Lab Med"}],"container-title":["Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0914508725000619?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0914508725000619?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T02:10:38Z","timestamp":1780279838000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0914508725000619"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":62,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S0914508725000619"],"URL":"https:\/\/doi.org\/10.1016\/j.jjcc.2025.02.013","relation":{},"ISSN":["0914-5087"],"issn-type":[{"value":"0914-5087","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of new anticoagulants targeting coagulation factor XI and prospects for clinical use","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jjcc.2025.02.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Japanese College of Cardiology. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}